Renal Cancer - Results from #2420

Organotypic primary blood vessel models of clear cell renal cell carcinoma for single-patient clinical trials. October 28, 2020

Differentiation of renal cell tumors with morphological cocktails using a minimal panel of immunohistochemical markers. October 28, 2020

Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE). October 28, 2020

Suppressive effects of RASAL2 on renal cell carcinoma via SOX2/ERK/p38 MAPK pathway. October 27, 2020

Prognostic value of plasminogen activator inhibitor-1 in biomarker exploration using multiplex immunoassay in patients with metastatic renal cell carcinoma treated with axitinib. October 27, 2020

A risk stratification model based on four novel biomarkers predicts prognosis for patients with renal cell carcinoma. October 27, 2020

Absorption of the orally active multikinase inhibitor axitinib as a therapeutic index to guide dose titration in metastatic renal cell carcinoma. October 26, 2020

Transplant Radical Nephrectomy and Transplant Radical Nephroureterectomy for Renal Cancer: Postoperative and Survival Outcomes. October 26, 2020

Dynamic 68Ga-PSMA-11 PET/CT for the primary evaluation of localized renal mass: a prospective study. October 26, 2020

Expression Profile Analysis of m6A RNA Methylation Regulators Indicates They Are Immune Signature Associated and Can Predict Survival in Kidney Renal Cell Carcinoma. October 23, 2020

HIF1α is not a target of 14q deletion in clear cell renal cancer. October 22, 2020

Everolimus after failure of one prior VEGF-targeted therapy in metastatic renal cell carcinoma: Final results of the MARC-2 trial. October 22, 2020

Folliculin deficient renal cancer cells exhibit BRCA1 A complex expression impairment and sensitivity to PARP1 inhibitor olaparib. October 22, 2020

Robot-assisted retroperitoneal lymphadenectomy in patient with type I papillary renal cancer recurrence after 5 years of follow-up. October 21, 2020

Cultivation of Clear Cell Renal Cell Carcinoma Patient-Derived Organoids in an Air-Liquid Interface System as a Tool for Studying Individualized Therapy. October 21, 2020

Long Non-coding RNA CCAT1 Acts as an Oncogene and Promotes Sunitinib Resistance in Renal Cell Carcinoma. October 21, 2020

Metastatic renal cell carcinoma to the pancreas: Clinical features and treatment outcome. October 20, 2020

Circulating Non-coding RNAs in Renal Cell Carcinoma-Pathogenesis and Potential Implications as Clinical Biomarkers. October 20, 2020

Association between copy-number alteration of +20q, -14q and -18p and cross-sensitivity to tyrosine kinase inhibitors in clear-cell renal cell carcinoma. October 20, 2020

U.S. Food and Drug Administration Accepts for Priority Review Applications for OPDIVO® (nivolumab) in Combination with CABOMETYX® (cabozantinib) in Advanced Renal Cell Carcinoma October 19, 2020

Page 122 of 456